Little data exist regarding infliximab use in surgical decision making and postoperative complications in ulcerative colitis.
Dr Mor and colleagues from Ohio, USA determined the rate of postoperative complications in infliximab-treated ulcerative colitis patients undergoing restorative proctocolectomy.
The researchers determined whether 3-stage procedures are more often necessary.
|The odds of early complication for the inflixmab group was 3.5 times that of controls|
|Diseases of the Colon & Rectum|
The team studied a group of infliximab-treated patients and matched control subjects who underwent two-stage restorative proctocolectomy between 2000 and 2006.
Postoperative complications were compared.
In addition, the rate of 3-stage procedures was compared between all infliximab- and noninfliximab-treated patients.
The researchers performed a total of 523 restorative proctocolectomies.
In the infliximab group, 46 were 2-stage and 39 were 3-stage procedures.
Covariate-adjusted odds of early complication for the inflixmab group was 3.5 times that of controls.
The research team found that the odds of sepsis were 14 times greater, and the odds of late complication were 2 times greater for infliximab.
The team observed that the odds of requirement for 3-stage procedures was 2 times greater in the infliximab group.
Dr Mor's team concluded, "Infliximab increases the risk of postoperative complications after restorative proctocolectomy and has altered the surgical approach to ulcerative colitis."
"Potential benefits of infliximab should be balanced against these risks."